Zydus Lifesciences gains on getting two final approvals from USFDA for Venlafaxine, Pregabalin
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 379.90, up by 1.85 points or 0.49% from its previous closing of Rs. 378.05 on the BSE.
The scrip opened at Rs. 380.00 and has touched a high and low of Rs. 384.55 and Rs. 378.55 respectively. So far 9946 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 393.70 and Rs. 371.05 respectively. The current market cap of the company is Rs. 38266.38 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 14.88% and 10.24% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Venlafaxine Extended-Release Tablets, USP 37.5 mg, 75 mg, 150 mg and 225 mg. USRLD: Venlafaxine Hydrochloride Extended-Release Tablets. The company also received the final approval from USFDA to market Pregabalin Extended-Release Tablets, USP 82.5 mg, 165 mg and 330 mg. USRLD: Lyrica CR.
Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It is expected to improve mood and energy levels in patients. The medication is also expected to decrease fear, anxiety, unwanted thoughts and the number of panic attacks. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. Venlafaxine Extended-Release tablets had annual sales of USD 46 million in the United States according to IQVIA MAT July 2022.
Pregabalin Extended-Release tablets are used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. Pregabalin Extended-Release tablets had annual sales of USD 3 million in the United States according to IQVIA MAT June 2022. The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
